WO2004056313A3 - Prevention and treatment of cardiac arrhythmias - Google Patents

Prevention and treatment of cardiac arrhythmias Download PDF

Info

Publication number
WO2004056313A3
WO2004056313A3 PCT/US2003/040504 US0340504W WO2004056313A3 WO 2004056313 A3 WO2004056313 A3 WO 2004056313A3 US 0340504 W US0340504 W US 0340504W WO 2004056313 A3 WO2004056313 A3 WO 2004056313A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prevention
cardiac arrhythmias
glucagon
peptide
Prior art date
Application number
PCT/US2003/040504
Other languages
French (fr)
Other versions
WO2004056313A2 (en
Inventor
David R Hathaway
Alain D Baron
Original Assignee
Amylin Pharmaceuticals Inc
David R Hathaway
Alain D Baron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, David R Hathaway, Alain D Baron filed Critical Amylin Pharmaceuticals Inc
Priority to AU2003297356A priority Critical patent/AU2003297356A1/en
Priority to JP2004562291A priority patent/JP2006514035A/en
Priority to EP03813770A priority patent/EP1610811A4/en
Publication of WO2004056313A2 publication Critical patent/WO2004056313A2/en
Publication of WO2004056313A3 publication Critical patent/WO2004056313A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an intecrin, a glucagon-like peptide-1 (GLP-1), an exendin, or an aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
PCT/US2003/040504 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias WO2004056313A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003297356A AU2003297356A1 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias
JP2004562291A JP2006514035A (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias
EP03813770A EP1610811A4 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US60/434,508 2002-12-17
US43488802P 2002-12-19 2002-12-19
US60/434,888 2002-12-19

Publications (2)

Publication Number Publication Date
WO2004056313A2 WO2004056313A2 (en) 2004-07-08
WO2004056313A3 true WO2004056313A3 (en) 2004-11-25

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Country Status (4)

Country Link
EP (1) EP1610811A4 (en)
JP (1) JP2006514035A (en)
AU (1) AU2003297356A1 (en)
WO (1) WO2004056313A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108939052A (en) * 2018-09-04 2018-12-07 江苏省中医药研究院 Purposes of the Exenatide in the drug of preparation prevention or treatment atrial fibrillation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005211776B2 (en) 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
KR101399178B1 (en) * 2005-08-11 2014-06-18 아스트라제네카 파마수티컬스 엘피 Hybrid polypeptides with selectable properties
WO2007139941A2 (en) * 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
RU2010113997A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) THYROLIBERIN FOR THERAPEUTIC USE
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2771025A1 (en) * 2011-10-28 2014-09-03 Pharis Biotec GmbH A polypeptide for the protection against heart ischemia-reperfusion injury
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
JP2016503771A (en) 2012-12-21 2016-02-08 サノフイ Exendin-4 derivative
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (en) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Peptide for medical treatment of pancreatic diabetes of 2nd type and its complications
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
CN111050750A (en) 2017-08-24 2020-04-21 诺沃挪第克公司 GLP-1 compositions and uses thereof
CN110551203B (en) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 Exenatide analogue
MX2022009523A (en) 2020-02-18 2022-09-09 Novo Nordisk As Pharmaceutical formulations.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020107206A1 (en) * 2000-05-19 2002-08-08 Coolidge Thomas R. Treatment of acute coronary syndrome with GLP-1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
AU759058C (en) * 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
DE60142351D1 (en) * 2000-10-20 2010-07-22 Amylin Pharmaceuticals Inc TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20020107206A1 (en) * 2000-05-19 2002-08-08 Coolidge Thomas R. Treatment of acute coronary syndrome with GLP-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIKOLAIDIS ET AL.: "GLP-1 improves myocardial performance in conscious dogs with pacing induced heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 37, no. 2, February 2001 (2001-02-01), pages 218A, XP001053523 *
See also references of EP1610811A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108939052A (en) * 2018-09-04 2018-12-07 江苏省中医药研究院 Purposes of the Exenatide in the drug of preparation prevention or treatment atrial fibrillation
CN108939052B (en) * 2018-09-04 2021-03-16 江苏省中医药研究院 Application of exenatide in preparation of medicine for preventing or treating atrial fibrillation

Also Published As

Publication number Publication date
EP1610811A4 (en) 2008-03-26
AU2003297356A8 (en) 2004-07-14
EP1610811A2 (en) 2006-01-04
AU2003297356A1 (en) 2004-07-14
JP2006514035A (en) 2006-04-27
WO2004056313A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
WO2004056313A3 (en) Prevention and treatment of cardiac arrhythmias
WO2000066138A3 (en) Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
WO2006110887A3 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
WO2004056317A3 (en) Compositions for the treatment and prevention of nephropathy
WO2006024275A3 (en) Glp-1 and exendin related invention
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
NO20010982L (en) Method of administering insulinotropic peptides
EA200300026A1 (en) GLUKAGONOPODODODNOGNY PEPTIDA-1 ANALOGUES
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
AU2003239478A8 (en) Modified glucagon-like peptide-1 analogs
AU2002322403A1 (en) Glucagon-like peptide-1 analogs
WO2005082928A3 (en) Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2006119260A3 (en) Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
DK1412357T3 (en) Beta-aminotetrahydroimidazo (1,2-a) pyrazines and tetrahydrotriazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1773330A4 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
EP1585959A4 (en) Extended glucagon-like peptide-1 analogs
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
DK1523325T3 (en) Methods and compositions for the treatment of polycystic ovarian syndrome
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
WO2006086727A3 (en) Treating diabetes with glucagon-like peptide-1 secretagogues
TW200616996A (en) Compounds, compositions and methods
WO2004099150A3 (en) 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
WO2007089336A3 (en) Certain chemical entities, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004562291

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003813770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003813770

Country of ref document: EP